The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT
Endometrial biopsies showing inadequate development were observed after ovarian stimulation with the GnRH agonist Buserelin and HMG for IVF or GIFT when luteal supplementation was omitted. Ninety-one patients were randomly allocated to two luteal supplementation regimens: in 41 women HCG and In 50 w...
Gespeichert in:
| Veröffentlicht in: | Human reproduction (Oxford) 1988-07, Vol.3 (5), p.585-590 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 590 |
|---|---|
| container_issue | 5 |
| container_start_page | 585 |
| container_title | Human reproduction (Oxford) |
| container_volume | 3 |
| creator | Smitz, J. Devroey, P. Camus, M. Deschacht, J. Khan, I. Staessen, C. Van Waesberghe, L. Wisanto, A. Van Steirteghem, A.C. |
| description | Endometrial biopsies showing inadequate development were observed after ovarian stimulation with the GnRH agonist Buserelin and HMG for IVF or GIFT when luteal supplementation was omitted. Ninety-one patients were randomly allocated to two luteal supplementation regimens: in 41 women HCG and In 50 women progesterone and oestradiol valerate. The pregnancy rate was similar for both supplementation regimens. In pregnant patients treated with a combination of the GnRH agonist and HMG a delay of implantation of 1.3 days was observed compared to pregnancies after domiphew citrate-HMG sthulation. This delay was not due to slower preimplantation embryo development after GnRH agonist-HMG treatment. Temporarily defective function of the corpus luteum was evidenced by measuring serum progesterone, 17β-oestradiol and 17-hydroxyprogesterone in the patients receiving progesterone and oestradiol valerate. This inadequate corpus luteum function could be related to the prolonged blockage of pituitary gonadotrophic function after arrest of the GnRH agonist. |
| doi_str_mv | 10.1093/oxfordjournals.humrep.a136750 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78462337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78462337</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-e531a63319e66ea80da52f2a5a294f96c79f3b126bf90670fde4ff6a3983b7e73</originalsourceid><addsrcrecordid>eNpVkE9r3DAQxUVpSbdpP0JBl_bmjeSxZevQQxu63oWUwrL9Qy9i1h5lndqSK9kl--3jsEsgpxl47808fox9kGIphYYrf299aO78FBx2cXmY-kDDEiWoIhcv2EJmSiQp5OIlW4hUlYmUSr5mb2K8E2JeS3XBLkCCVrpcsGF3IN5NI2HHhwNG4ugaThi6Ix8C3Tp09ZGjHSnw2vf71lHDK7ddJ3jrXRvHq_W3io-BcOzJjXzuxuM0UPD_pw7H1jveOr75ueKzUG1Wu7fslZ1707vzvGQ_Vl931-vk5nu1uf58k9SQl2NCOUhUAFKTUoSlaDBPbYo5pjqzWtWFtrCXqdpbLVQhbEOZtQpBl7AvqIBL9vF0dwj-30RxNH0ba-o6dOSnaIoyUynAo_HTyVgHH2Mga4bQ9hiORgrzSNw8J25OxM2Z-Jx_f3407XtqntJnxLOenPQZFt0_yRj-GlVAkZv17z8GttWvL3oLJoMH0saU6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78462337</pqid></control><display><type>article</type><title>The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT</title><source>Oxford University Press Journals Digital Archive legacy</source><source>MEDLINE</source><creator>Smitz, J. ; Devroey, P. ; Camus, M. ; Deschacht, J. ; Khan, I. ; Staessen, C. ; Van Waesberghe, L. ; Wisanto, A. ; Van Steirteghem, A.C.</creator><creatorcontrib>Smitz, J. ; Devroey, P. ; Camus, M. ; Deschacht, J. ; Khan, I. ; Staessen, C. ; Van Waesberghe, L. ; Wisanto, A. ; Van Steirteghem, A.C.</creatorcontrib><description>Endometrial biopsies showing inadequate development were observed after ovarian stimulation with the GnRH agonist Buserelin and HMG for IVF or GIFT when luteal supplementation was omitted. Ninety-one patients were randomly allocated to two luteal supplementation regimens: in 41 women HCG and In 50 women progesterone and oestradiol valerate. The pregnancy rate was similar for both supplementation regimens. In pregnant patients treated with a combination of the GnRH agonist and HMG a delay of implantation of 1.3 days was observed compared to pregnancies after domiphew citrate-HMG sthulation. This delay was not due to slower preimplantation embryo development after GnRH agonist-HMG treatment. Temporarily defective function of the corpus luteum was evidenced by measuring serum progesterone, 17β-oestradiol and 17-hydroxyprogesterone in the patients receiving progesterone and oestradiol valerate. This inadequate corpus luteum function could be related to the prolonged blockage of pituitary gonadotrophic function after arrest of the GnRH agonist.</description><identifier>ISSN: 0268-1161</identifier><identifier>EISSN: 1460-2350</identifier><identifier>DOI: 10.1093/oxfordjournals.humrep.a136750</identifier><identifier>PMID: 3139698</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Buserelin - therapeutic use ; Female ; Fertilization in Vitro ; GIFT ; GnRH agonist ; Hormones - blood ; Humans ; IVF ; luteal phase ; Luteal Phase - drug effects ; Menotropins - therapeutic use ; Ovulation - drug effects ; Ovulation Induction ; Pregnancy ; Progesterone - pharmacology ; Random Allocation ; Superovulation - drug effects</subject><ispartof>Human reproduction (Oxford), 1988-07, Vol.3 (5), p.585-590</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-e531a63319e66ea80da52f2a5a294f96c79f3b126bf90670fde4ff6a3983b7e73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3139698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smitz, J.</creatorcontrib><creatorcontrib>Devroey, P.</creatorcontrib><creatorcontrib>Camus, M.</creatorcontrib><creatorcontrib>Deschacht, J.</creatorcontrib><creatorcontrib>Khan, I.</creatorcontrib><creatorcontrib>Staessen, C.</creatorcontrib><creatorcontrib>Van Waesberghe, L.</creatorcontrib><creatorcontrib>Wisanto, A.</creatorcontrib><creatorcontrib>Van Steirteghem, A.C.</creatorcontrib><title>The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT</title><title>Human reproduction (Oxford)</title><addtitle>Hum Reprod</addtitle><description>Endometrial biopsies showing inadequate development were observed after ovarian stimulation with the GnRH agonist Buserelin and HMG for IVF or GIFT when luteal supplementation was omitted. Ninety-one patients were randomly allocated to two luteal supplementation regimens: in 41 women HCG and In 50 women progesterone and oestradiol valerate. The pregnancy rate was similar for both supplementation regimens. In pregnant patients treated with a combination of the GnRH agonist and HMG a delay of implantation of 1.3 days was observed compared to pregnancies after domiphew citrate-HMG sthulation. This delay was not due to slower preimplantation embryo development after GnRH agonist-HMG treatment. Temporarily defective function of the corpus luteum was evidenced by measuring serum progesterone, 17β-oestradiol and 17-hydroxyprogesterone in the patients receiving progesterone and oestradiol valerate. This inadequate corpus luteum function could be related to the prolonged blockage of pituitary gonadotrophic function after arrest of the GnRH agonist.</description><subject>Buserelin - therapeutic use</subject><subject>Female</subject><subject>Fertilization in Vitro</subject><subject>GIFT</subject><subject>GnRH agonist</subject><subject>Hormones - blood</subject><subject>Humans</subject><subject>IVF</subject><subject>luteal phase</subject><subject>Luteal Phase - drug effects</subject><subject>Menotropins - therapeutic use</subject><subject>Ovulation - drug effects</subject><subject>Ovulation Induction</subject><subject>Pregnancy</subject><subject>Progesterone - pharmacology</subject><subject>Random Allocation</subject><subject>Superovulation - drug effects</subject><issn>0268-1161</issn><issn>1460-2350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE9r3DAQxUVpSbdpP0JBl_bmjeSxZevQQxu63oWUwrL9Qy9i1h5lndqSK9kl--3jsEsgpxl47808fox9kGIphYYrf299aO78FBx2cXmY-kDDEiWoIhcv2EJmSiQp5OIlW4hUlYmUSr5mb2K8E2JeS3XBLkCCVrpcsGF3IN5NI2HHhwNG4ugaThi6Ix8C3Tp09ZGjHSnw2vf71lHDK7ddJ3jrXRvHq_W3io-BcOzJjXzuxuM0UPD_pw7H1jveOr75ueKzUG1Wu7fslZ1707vzvGQ_Vl931-vk5nu1uf58k9SQl2NCOUhUAFKTUoSlaDBPbYo5pjqzWtWFtrCXqdpbLVQhbEOZtQpBl7AvqIBL9vF0dwj-30RxNH0ba-o6dOSnaIoyUynAo_HTyVgHH2Mga4bQ9hiORgrzSNw8J25OxM2Z-Jx_f3407XtqntJnxLOenPQZFt0_yRj-GlVAkZv17z8GttWvL3oLJoMH0saU6g</recordid><startdate>19880701</startdate><enddate>19880701</enddate><creator>Smitz, J.</creator><creator>Devroey, P.</creator><creator>Camus, M.</creator><creator>Deschacht, J.</creator><creator>Khan, I.</creator><creator>Staessen, C.</creator><creator>Van Waesberghe, L.</creator><creator>Wisanto, A.</creator><creator>Van Steirteghem, A.C.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19880701</creationdate><title>The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT</title><author>Smitz, J. ; Devroey, P. ; Camus, M. ; Deschacht, J. ; Khan, I. ; Staessen, C. ; Van Waesberghe, L. ; Wisanto, A. ; Van Steirteghem, A.C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-e531a63319e66ea80da52f2a5a294f96c79f3b126bf90670fde4ff6a3983b7e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Buserelin - therapeutic use</topic><topic>Female</topic><topic>Fertilization in Vitro</topic><topic>GIFT</topic><topic>GnRH agonist</topic><topic>Hormones - blood</topic><topic>Humans</topic><topic>IVF</topic><topic>luteal phase</topic><topic>Luteal Phase - drug effects</topic><topic>Menotropins - therapeutic use</topic><topic>Ovulation - drug effects</topic><topic>Ovulation Induction</topic><topic>Pregnancy</topic><topic>Progesterone - pharmacology</topic><topic>Random Allocation</topic><topic>Superovulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smitz, J.</creatorcontrib><creatorcontrib>Devroey, P.</creatorcontrib><creatorcontrib>Camus, M.</creatorcontrib><creatorcontrib>Deschacht, J.</creatorcontrib><creatorcontrib>Khan, I.</creatorcontrib><creatorcontrib>Staessen, C.</creatorcontrib><creatorcontrib>Van Waesberghe, L.</creatorcontrib><creatorcontrib>Wisanto, A.</creatorcontrib><creatorcontrib>Van Steirteghem, A.C.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Human reproduction (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smitz, J.</au><au>Devroey, P.</au><au>Camus, M.</au><au>Deschacht, J.</au><au>Khan, I.</au><au>Staessen, C.</au><au>Van Waesberghe, L.</au><au>Wisanto, A.</au><au>Van Steirteghem, A.C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT</atitle><jtitle>Human reproduction (Oxford)</jtitle><addtitle>Hum Reprod</addtitle><date>1988-07-01</date><risdate>1988</risdate><volume>3</volume><issue>5</issue><spage>585</spage><epage>590</epage><pages>585-590</pages><issn>0268-1161</issn><eissn>1460-2350</eissn><abstract>Endometrial biopsies showing inadequate development were observed after ovarian stimulation with the GnRH agonist Buserelin and HMG for IVF or GIFT when luteal supplementation was omitted. Ninety-one patients were randomly allocated to two luteal supplementation regimens: in 41 women HCG and In 50 women progesterone and oestradiol valerate. The pregnancy rate was similar for both supplementation regimens. In pregnant patients treated with a combination of the GnRH agonist and HMG a delay of implantation of 1.3 days was observed compared to pregnancies after domiphew citrate-HMG sthulation. This delay was not due to slower preimplantation embryo development after GnRH agonist-HMG treatment. Temporarily defective function of the corpus luteum was evidenced by measuring serum progesterone, 17β-oestradiol and 17-hydroxyprogesterone in the patients receiving progesterone and oestradiol valerate. This inadequate corpus luteum function could be related to the prolonged blockage of pituitary gonadotrophic function after arrest of the GnRH agonist.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>3139698</pmid><doi>10.1093/oxfordjournals.humrep.a136750</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-1161 |
| ispartof | Human reproduction (Oxford), 1988-07, Vol.3 (5), p.585-590 |
| issn | 0268-1161 1460-2350 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78462337 |
| source | Oxford University Press Journals Digital Archive legacy; MEDLINE |
| subjects | Buserelin - therapeutic use Female Fertilization in Vitro GIFT GnRH agonist Hormones - blood Humans IVF luteal phase Luteal Phase - drug effects Menotropins - therapeutic use Ovulation - drug effects Ovulation Induction Pregnancy Progesterone - pharmacology Random Allocation Superovulation - drug effects |
| title | The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T23%3A55%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20luteal%20phase%20and%20early%20pregnancy%20after%20combined%20GnRH-agonist/HMG%20treatment%20for%20superovulation%20in%20IVF%20or%20GIFT&rft.jtitle=Human%20reproduction%20(Oxford)&rft.au=Smitz,%20J.&rft.date=1988-07-01&rft.volume=3&rft.issue=5&rft.spage=585&rft.epage=590&rft.pages=585-590&rft.issn=0268-1161&rft.eissn=1460-2350&rft_id=info:doi/10.1093/oxfordjournals.humrep.a136750&rft_dat=%3Cproquest_cross%3E78462337%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78462337&rft_id=info:pmid/3139698&rfr_iscdi=true |